Yoshinobu Koguchi

Has grant

Associate Professor (Research)

Ohio State University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Yoshinobu Koguchi is an Associate Professor (Research) at The Ohio State University in the United States. His research focuses on cancer immunotherapy, particularly in the mechanisms of immune response and the development of novel biomarkers for treatment efficacy. His recent publications explore topics such as checkpoint blockade responses, immune infiltrate analysis in tumors, and the optimization of therapeutic strategies in various cancer types.

Recent Grants

Grant: Close

Transcriptome and genomic analysis of antigen-specific CD8 T cells in long-term melanoma survivors

Open Date: 2014-05-01

Close Date: 2015-04-01

Grant: Close

Negative Regulation of iNKT Cell Development by Non-canonical NF-kappaB

Open Date: 2012-09-01

Close Date: 2013-07-01

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Yiyi Chen

Associate Professor

Oregon Health & Science University

UNITED STATES

View details

Xiyu Peng

Assistant Professor

Texas A&M University

UNITED STATES

View details

Rom Leidner

UNITED STATES

View details

Eric Tran

National Institutes of Health

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yoshinobu Koguchi

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming

Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.

A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

Collaborators (4)

Yiyi Chen

Xiyu Peng

Rom Leidner

Eric Tran

Make your next move.